162 related articles for article (PubMed ID: 31560094)
21. Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells.
Scharer CD; McCabe CD; Ali-Seyed M; Berger MF; Bulyk ML; Moreno CS
Cancer Res; 2009 Jan; 69(2):709-17. PubMed ID: 19147588
[TBL] [Abstract][Full Text] [Related]
22. Alterations of C-MYC, NKX3.1, and E-cadherin expression in canine prostate carcinogenesis.
Fonseca-Alves CE; Rodrigues MM; de Moura VM; Rogatto SR; Laufer-Amorim R
Microsc Res Tech; 2013 Dec; 76(12):1250-6. PubMed ID: 24030851
[TBL] [Abstract][Full Text] [Related]
23. SOX4 induces tumor invasion by targeting EMT-related pathway in prostate cancer.
Liu Y; Zeng S; Jiang X; Lai D; Su Z
Tumour Biol; 2017 May; 39(5):1010428317694539. PubMed ID: 28466783
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of SOX18 promotes prostate cancer progression via the regulation of TCF1, c-Myc, cyclin D1 and MMP-7.
Yin H; Sheng Z; Zhang X; Du Y; Qin C; Liu H; Dun Y; Wang Q; Jin C; Zhao Y; Xu T
Oncol Rep; 2017 Feb; 37(2):1045-1051. PubMed ID: 27922675
[TBL] [Abstract][Full Text] [Related]
25. SOX4 is associated with poor prognosis in cholangiocarcinoma.
Wang W; Zhang J; Zhan X; Lin T; Yang M; Hu J; Han B; Hu S
Biochem Biophys Res Commun; 2014 Sep; 452(3):614-21. PubMed ID: 25181339
[TBL] [Abstract][Full Text] [Related]
26. SOX4 is a potential prognostic factor in human cancers: a systematic review and meta-analysis.
Chen J; Ju HL; Yuan XY; Wang TJ; Lai BQ
Clin Transl Oncol; 2016 Jan; 18(1):65-72. PubMed ID: 26250764
[TBL] [Abstract][Full Text] [Related]
27. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
[TBL] [Abstract][Full Text] [Related]
28. Metformin targets c-MYC oncogene to prevent prostate cancer.
Akinyeke T; Matsumura S; Wang X; Wu Y; Schalfer ED; Saxena A; Yan W; Logan SK; Li X
Carcinogenesis; 2013 Dec; 34(12):2823-32. PubMed ID: 24130167
[TBL] [Abstract][Full Text] [Related]
29. A regulatory circuit HP1γ/miR-451a/c-Myc promotes prostate cancer progression.
Chang C; Liu J; He W; Qu M; Huang X; Deng Y; Shen L; Zhao X; Guo H; Jiang J; Fu XY; Huang R; Zhang D; Yan J
Oncogene; 2018 Jan; 37(4):415-426. PubMed ID: 28967902
[TBL] [Abstract][Full Text] [Related]
30. SREBP-2 promotes stem cell-like properties and metastasis by transcriptional activation of c-Myc in prostate cancer.
Li X; Wu JB; Li Q; Shigemura K; Chung LW; Huang WC
Oncotarget; 2016 Mar; 7(11):12869-84. PubMed ID: 26883200
[TBL] [Abstract][Full Text] [Related]
31. Myc-dependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer.
Barfeld SJ; Fazli L; Persson M; Marjavaara L; Urbanucci A; Kaukoniemi KM; Rennie PS; Ceder Y; Chabes A; Visakorpi T; Mills IG
Oncotarget; 2015 May; 6(14):12587-602. PubMed ID: 25869206
[TBL] [Abstract][Full Text] [Related]
32. CIP2A mediates prostate cancer progression via the c-Myc signaling pathway.
Guo Z; Liu D; Su Z
Tumour Biol; 2015 Jun; 36(6):4777-83. PubMed ID: 25636449
[TBL] [Abstract][Full Text] [Related]
33. A molecularly genetic determination of prognostic factors of the prostate cancer and their relationships to expression of protein p27kip1.
Dvorácková J; Uvírová M
Neoplasma; 2007; 54(2):149-54. PubMed ID: 17319789
[TBL] [Abstract][Full Text] [Related]
34. Targeting SMYD2 inhibits prostate cancer cell growth by regulating c-Myc signaling.
Li J; Wan F; Zhang J; Zheng S; Yang Y; Hong Z; Dai B
Mol Carcinog; 2023 Jul; 62(7):940-950. PubMed ID: 37036190
[TBL] [Abstract][Full Text] [Related]
35. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells.
Liu P; Ramachandran S; Ali Seyed M; Scharer CD; Laycock N; Dalton WB; Williams H; Karanam S; Datta MW; Jaye DL; Moreno CS
Cancer Res; 2006 Apr; 66(8):4011-9. PubMed ID: 16618720
[TBL] [Abstract][Full Text] [Related]
36. Analysis of genetic aberrations on chromosomal region 8q21-24 identifies E2F5 as an oncogene with copy number gain in prostate cancer.
Zhao J; Wu XY; Ling XH; Lin ZY; Fu X; Deng YH; He HC; Zhong W
Med Oncol; 2013 Mar; 30(1):465. PubMed ID: 23377984
[TBL] [Abstract][Full Text] [Related]
37. SOX4 is overexpressed in diffusely infiltrating astrocytoma and confers poor prognosis.
Li L; Li Q; Chen X; Xu M; Li X; Nie L; Chen N; Gong J; Mao Q; Zhou Q
Neuropathology; 2015 Dec; 35(6):510-7. PubMed ID: 26096696
[TBL] [Abstract][Full Text] [Related]
38. [Relationship between chromosome 8 alterations and Gleason score in prostatic adenocarcinoma].
Zeng X; Wu SF; Xu Q; Xiao Y; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):523-8. PubMed ID: 17134545
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of ETV4 is associated with poor prognosis in prostate cancer: involvement of uPA/uPAR and MMPs.
Qi M; Liu Z; Shen C; Wang L; Zeng J; Wang C; Li C; Fu W; Sun Y; Han B
Tumour Biol; 2015 May; 36(5):3565-72. PubMed ID: 25544710
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression.
Tan Y; Wang L; Du Y; Liu X; Chen Z; Weng X; Guo J; Chen H; Wang M; Wang X
Int J Oncol; 2018 Dec; 53(6):2503-2517. PubMed ID: 30272279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
